Compare Eni SpA (E) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Summit Therapeutics Inc — how do they compare? Eni SpA trades at $48.17 (market cap $70.34B), while Summit Therapeutics Inc trades at $13.96 (market cap $11.70B). The key difference: Eni SpA is far larger — about 6× Summit Therapeutics Inc's market cap, and Eni SpA pays a 4.99% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| E | SMMT | |
|---|---|---|
Market Cap | $70.34B | $11.70B |
Sector | Energy | Health |
52-Week High | $57.61 | $29.32 |
52-Week Low | $32.93 | $13.05 |
Enterprise Value | $89.25B | $11.12B |
Dividend Yield | 4.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $48.11, down 2.91% over 24 hours, with a bullish technical signal supported by moving averages but mixed oscillators. The company shows stable cash flow generation with $238 million net cash flow in 2025, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent strategic moves include expanding into lithium, battery storage, and fusion energy partnerships, signaling diversification beyond traditional oil and gas.
The outlook balances diversification efforts against revenue pressures; the stock's low P/S of 0.79 and EV/EBITDA of 3.83 suggest undervaluation, but investors face risks from oil price volatility and execution challenges in new ventures. Analyst consensus is cautious with 61.53% hold ratings, reflecting uncertainty amid transition initiatives.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
